Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Historique:
received: 23 09 2018
revised: 30 01 2019
accepted: 18 02 2019
entrez: 11 8 2019
pubmed: 11 8 2019
medline: 4 12 2019
Statut: ppublish

Résumé

Liver transplantation (LT) and liver resection (LR) are curative treatment options for patients with hepatocellular carcinoma within the Milan criteria. Severe organ shortage dictates the preference for LR. Our aim was to provide an intention-to-treat retrospective comparison of survival between patients who were placed on waiting lists for LT and those who underwent LR. The medical records of patients with hepatocellular carcinoma within the Milan criteria treated by LR or listed for LT between 2007 and 2016 were reviewed. We performed intention-to-treat analyses of overall survival and recurrence. There were 54 patients on the waiting list for LT, and 30 of them underwent LR. Thirteen of the 54 patients (24%) were not transplanted because of disease-related mortality or tumor progression. The median waiting time to transplantation was 304 days. The 90-day mortality was higher in transplanted patients (9.8% vs 3.3%, P = .003). Intention-to-treat survival was similar for the LT and LR groups (5-year survival, 47.8% vs 55%, respectively, P = .185). There was a trend toward improved 5-year disease-free survival for listed patients (56.2% vs 26.3% for patients undergoing LR, P = .15). Intention-to-treat survival is similar in patients undergoing LR and those on waiting lists for LT. There is a 24% risk to drop from the transplant list. The higher perioperative mortality among patients undergoing LT is balanced by a higher tumor recurrence rate after LR.

Sections du résumé

BACKGROUND BACKGROUND
Liver transplantation (LT) and liver resection (LR) are curative treatment options for patients with hepatocellular carcinoma within the Milan criteria. Severe organ shortage dictates the preference for LR. Our aim was to provide an intention-to-treat retrospective comparison of survival between patients who were placed on waiting lists for LT and those who underwent LR.
METHODS METHODS
The medical records of patients with hepatocellular carcinoma within the Milan criteria treated by LR or listed for LT between 2007 and 2016 were reviewed. We performed intention-to-treat analyses of overall survival and recurrence.
RESULTS RESULTS
There were 54 patients on the waiting list for LT, and 30 of them underwent LR. Thirteen of the 54 patients (24%) were not transplanted because of disease-related mortality or tumor progression. The median waiting time to transplantation was 304 days. The 90-day mortality was higher in transplanted patients (9.8% vs 3.3%, P = .003). Intention-to-treat survival was similar for the LT and LR groups (5-year survival, 47.8% vs 55%, respectively, P = .185). There was a trend toward improved 5-year disease-free survival for listed patients (56.2% vs 26.3% for patients undergoing LR, P = .15).
CONCLUSION CONCLUSIONS
Intention-to-treat survival is similar in patients undergoing LR and those on waiting lists for LT. There is a 24% risk to drop from the transplant list. The higher perioperative mortality among patients undergoing LT is balanced by a higher tumor recurrence rate after LR.

Identifiants

pubmed: 31399171
pii: S0041-1345(18)31206-5
doi: 10.1016/j.transproceed.2019.02.030
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1867-1873

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Guy Meyerovich (G)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Yaacov Goykhman (Y)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Richard Nakache (R)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Ido Nachmany (I)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Guy Lahat (G)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Oren Shibolet (O)

Institute of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel.

Yoram Menachem (Y)

Institute of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel.

Helena Katchman (H)

Institute of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel.

Ido Wolf (I)

Institute of Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.

Ravit Geva (R)

Institute of Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.

Joseph M Klausner (JM)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel.

Nir Lubezky (N)

Department of Surgery, Tel Aviv Medical Center, Tel Aviv, Israel. Electronic address: nirl@tlvmc.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH